At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
LXRX Lexicon Pharmaceuticals
Trading 01-16 10:15:38 EST
1.33
+0.05
+3.52%
High1.34Low1.26Vol632.77K
Open1.28D1 Closing1.28Amplitude6.25%
Mkt Cap481.50MTradable Cap243.65MTotal Shares363.40M
T/O815.90KT/O Rate0.34%Tradable Shares183.89M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Analysts Offer Insights on Healthcare Companies: Centessa Pharmaceuticals (CNTA), Lexicon Pharmaceuticals (LXRX) and Alkermes (ALKS)
TIPRANKS  ·  21:01
Analysts Offer Insights on Healthcare Companies: Centessa Pharmaceuticals (CNTA), Lexicon Pharmaceuticals (LXRX) and Alkermes (ALKS)
Lexicon Pharmaceuticals Announces Pipeline Progress and Milestone Payment at J.P. Morgan Healthcare Conference
Reuters  ·  01-12
Lexicon Pharmaceuticals Announces Pipeline Progress and Milestone Payment at J.P. Morgan Healthcare Conference
Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44TH Annual J.p. Morgan Healthcare Conference
THOMSON REUTERS  ·  01-12
Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44TH Annual J.p. Morgan Healthcare Conference
Lexicon Pharmaceuticals Hosts Roundtable on Expanding Access to Non-Opioid Pain Treatments
Reuters  ·  01-09
Lexicon Pharmaceuticals Hosts Roundtable on Expanding Access to Non-Opioid Pain Treatments
Lexicon Pharmaceuticals Signs Exclusive Global Licensing Agreement for LX9851 with Novo Nordisk
Reuters  ·  2025-12-10
Lexicon Pharmaceuticals Signs Exclusive Global Licensing Agreement for LX9851 with Novo Nordisk
Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851
GlobeNewswire  ·  2025-12-10
Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851
Lexicon Pharmaceuticals to Present New Sotagliflozin Data on Adipose Distribution in Non-Diabetic HFpEF Patients
Reuters  ·  2025-12-05
Lexicon Pharmaceuticals to Present New Sotagliflozin Data on Adipose Distribution in Non-Diabetic HFpEF Patients
Lexicon Pharmaceuticals to Present at Piper Sandler and Evercore Healthcare Conferences
Reuters  ·  2025-11-25
Lexicon Pharmaceuticals to Present at Piper Sandler and Evercore Healthcare Conferences
Lexicon Pharmaceuticals Inc Files For Offering Of Up To $75 Million Of Common Stock - SEC Filing
Reuters  ·  2025-11-20
Lexicon Pharmaceuticals Inc Files For Offering Of Up To $75 Million Of Common Stock - SEC Filing
Lexicon Pharmaceuticals Q3 EPS USD -0.04
Reuters  ·  2025-11-20
Lexicon Pharmaceuticals Q3 EPS USD -0.04
Stock Track | Lexicon Pharmaceuticals Surges 5.28% on Upcoming Jefferies Conference Participation
Stock Track  ·  2025-11-12
Stock Track | Lexicon Pharmaceuticals Surges 5.28% on Upcoming Jefferies Conference Participation
Stock Track | Lexicon Pharmaceuticals Soars 5.28% on Upcoming Jefferies Conference Participation
Stock Track  ·  2025-11-12
Stock Track | Lexicon Pharmaceuticals Soars 5.28% on Upcoming Jefferies Conference Participation
Lexicon Pharmaceuticals to Join Jefferies London Healthcare Conference
Reuters  ·  2025-11-11
Lexicon Pharmaceuticals to Join Jefferies London Healthcare Conference
Lexicon Study Finds Sotagliflozin Improves Outcomes in HFpEF Patients Without Diabetes
Reuters  ·  2025-11-10
Lexicon Study Finds Sotagliflozin Improves Outcomes in HFpEF Patients Without Diabetes
Lexicon announces new sotagliflozin clinical data at AHA Sessions 2025
TIPRANKS  ·  2025-11-10
Lexicon announces new sotagliflozin clinical data at AHA Sessions 2025
Stock Track | Lexicon Pharmaceuticals Plummets 5.24% Pre-Market on $75 Million Stock Offering News
Stock Track  ·  2025-11-07
Stock Track | Lexicon Pharmaceuticals Plummets 5.24% Pre-Market on $75 Million Stock Offering News
Stock Track | Lexicon Pharmaceuticals Plummets 5.24% Following $75 Million Stock Offering Announcement
Stock Track  ·  2025-11-07
Stock Track | Lexicon Pharmaceuticals Plummets 5.24% Following $75 Million Stock Offering Announcement
Stock Track | Lexicon Pharmaceuticals Plunges 7.69% on $75 Million Stock Offering Announcement
Stock Track  ·  2025-11-07
Stock Track | Lexicon Pharmaceuticals Plunges 7.69% on $75 Million Stock Offering Announcement
BRIEF-Lexicon Pharmaceuticals Inc Files For Offering Of Up To $75 Million Of Common Stock - SEC Filing
Reuters  ·  2025-11-07
BRIEF-Lexicon Pharmaceuticals Inc Files For Offering Of Up To $75 Million Of Common Stock - SEC Filing
Lexicon Pharmaceuticals Files Prospectus for Stock Sale
TIPRANKS  ·  2025-11-07
Lexicon Pharmaceuticals Files Prospectus for Stock Sale

Introduction

Company Name.
Lexicon Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Issue price:
--